AIM: To investigate the safety and utility of an electrocautery dilation catheter for endoscopic ultrasonography (EUS)-guided pancreatic fluid collection drainage. METHODS: A single-center, exploratory, retrospective study was conducted between August 2010 and August 2014. This study was approved by the Medical Ethics Committee of our institution. Informed, written consent was obtained from each patient prior to the procedure. The subjects included 28 consecutive patients who underwent EUS-guided transmural drainage (EUS-TD) for symptomatic pancreatic and peripancreatic fluid collections (PFCs) by fine needle aspiration using a 19-gauge needle. These patients were retrospectively divided into two groups based on the use of an electrocautery dilation catheter as a fistula dilation device; 15 patients were treated with an electrocautery dilation catheter (electrocautery group), and 13 patients were treated with a non-electrocautery dilation catheter (non-electrocautery group). We evaluated the technical and clinical successes and the adverse events associated with EUS-TD for the treatment of PFCs between the two groups. RESULTS: There were no significant differences in age, sex, type, location and diameter of PFCs between the groups. Thirteen patients (87%) in the electrocautery group and 10 patients (77%) in the non-electrocautery group presented with infected PFCs. The technical success rates of EUS-TD for the treatment of PFCs were 100% (15/15) and 100% (13/13) for the electrocautery and the non-electrocautery groups, respectively. The clinical success rates of EUS-TD for the treatment of PFCs were 67% (10/15) and 69% (9/13) for the electrocautery and the non-electrocautery groups, respectively (P = 0.794). The procedure time of EUS-TD for the treatment of PFCs in the electrocautery group was significantly shorter than that of the non-electrocautery group (mean ± SD: 30 ± 12 min vs 52 ± 20 min, P < 0.001). Adverse events associated with EUS-TD for the treatment of PFCs occurred in 0 patients and 1 patient for the electrocautery and the non-electrocautery groups, respectively (P = 0.942). CONCLUSION: EUS-TD using an electrocautery dilation catheter as a fistula dilation device for the treatment of symptomatic PFCs appears safe and contributes to a shorter procedure time.
AIM: To investigate the safety and utility of an electrocautery dilation catheter for endoscopic ultrasonography (EUS)-guided pancreatic fluid collection drainage. METHODS: A single-center, exploratory, retrospective study was conducted between August 2010 and August 2014. This study was approved by the Medical Ethics Committee of our institution. Informed, written consent was obtained from each patient prior to the procedure. The subjects included 28 consecutive patients who underwent EUS-guided transmural drainage (EUS-TD) for symptomatic pancreatic and peripancreatic fluid collections (PFCs) by fine needle aspiration using a 19-gauge needle. These patients were retrospectively divided into two groups based on the use of an electrocautery dilation catheter as a fistula dilation device; 15 patients were treated with an electrocautery dilation catheter (electrocautery group), and 13 patients were treated with a non-electrocautery dilation catheter (non-electrocautery group). We evaluated the technical and clinical successes and the adverse events associated with EUS-TD for the treatment of PFCs between the two groups. RESULTS: There were no significant differences in age, sex, type, location and diameter of PFCs between the groups. Thirteen patients (87%) in the electrocautery group and 10 patients (77%) in the non-electrocautery group presented with infected PFCs. The technical success rates of EUS-TD for the treatment of PFCs were 100% (15/15) and 100% (13/13) for the electrocautery and the non-electrocautery groups, respectively. The clinical success rates of EUS-TD for the treatment of PFCs were 67% (10/15) and 69% (9/13) for the electrocautery and the non-electrocautery groups, respectively (P = 0.794). The procedure time of EUS-TD for the treatment of PFCs in the electrocautery group was significantly shorter than that of the non-electrocautery group (mean ± SD: 30 ± 12 min vs 52 ± 20 min, P < 0.001). Adverse events associated with EUS-TD for the treatment of PFCs occurred in 0 patients and 1 patient for the electrocautery and the non-electrocautery groups, respectively (P = 0.942). CONCLUSION: EUS-TD using an electrocautery dilation catheter as a fistula dilation device for the treatment of symptomatic PFCs appears safe and contributes to a shorter procedure time.
Entities:
Keywords:
Electrocautery dilation catheter; Endoscopic ultrasonography-guided transmural drainage; Fistula dilation device; Pancreatic and peripancreatic fluid collection; Procedure time
Authors: Stefan Seewald; Frank Thonke; Tiing-Leong Ang; Salem Omar; Uwe Seitz; Stefan Groth; Yan Zhong; Emre Yekebas; Jakob Izbicki; Nib Soehendra Journal: Gastrointest Endosc Date: 2006-11 Impact factor: 9.427
Authors: Venkata S Akshintala; Payal Saxena; Atif Zaheer; Uzma Rana; Susan M Hutfless; Anne Marie Lennon; Marcia I Canto; Anthony N Kalloo; Mouen A Khashab; Vikesh K Singh Journal: Gastrointest Endosc Date: 2013-12-04 Impact factor: 9.427
Authors: Shyam Varadarajulu; Ji Young Bang; Bryce S Sutton; Jessica M Trevino; John D Christein; C Mel Wilcox Journal: Gastroenterology Date: 2013-05-31 Impact factor: 22.682
Authors: Timothy B Gardner; Prabhleen Chahal; Georgios I Papachristou; Santhi Swaroop Vege; Bret T Petersen; Christopher J Gostout; Mark D Topazian; Naoki Takahashi; Michael G Sarr; Todd H Baron Journal: Gastrointest Endosc Date: 2009-02-24 Impact factor: 9.427
Authors: Sandra van Brunschot; Janneke van Grinsven; Rogier P Voermans; Olaf J Bakker; Marc G H Besselink; Marja A Boermeester; Thomas L Bollen; Koop Bosscha; Stefan A Bouwense; Marco J Bruno; Vincent C Cappendijk; Esther C Consten; Cornelis H Dejong; Marcel G W Dijkgraaf; Casper H van Eijck; G Willemien Erkelens; Harry van Goor; Mohammed Hadithi; Jan-Willem Haveman; Sijbrand H Hofker; Jeroen J M Jansen; Johan S Laméris; Krijn P van Lienden; Eric R Manusama; Maarten A Meijssen; Chris J Mulder; Vincent B Nieuwenhuis; Jan-Werner Poley; Rogier J de Ridder; Camiel Rosman; Alexander F Schaapherder; Joris J Scheepers; Erik J Schoon; Tom Seerden; B W Marcel Spanier; Jan Willem A Straathof; Robin Timmer; Niels G Venneman; Frank P Vleggaar; Ben J Witteman; Hein G Gooszen; Hjalmar C van Santvoort; Paul Fockens Journal: BMC Gastroenterol Date: 2013-11-25 Impact factor: 3.067